SG11202010322XA - Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes - Google Patents

Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Info

Publication number
SG11202010322XA
SG11202010322XA SG11202010322XA SG11202010322XA SG11202010322XA SG 11202010322X A SG11202010322X A SG 11202010322XA SG 11202010322X A SG11202010322X A SG 11202010322XA SG 11202010322X A SG11202010322X A SG 11202010322XA SG 11202010322X A SG11202010322X A SG 11202010322XA
Authority
SG
Singapore
Prior art keywords
diabetes
film
treatment
coated tablet
triazine derivative
Prior art date
Application number
SG11202010322XA
Inventor
Sébastien Bolze
Maxime Laugier
Original Assignee
Poxel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel filed Critical Poxel
Publication of SG11202010322XA publication Critical patent/SG11202010322XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202010322XA 2018-06-14 2019-06-11 Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes SG11202010322XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305730 2018-06-14
PCT/EP2019/065158 WO2019238647A1 (en) 2018-06-14 2019-06-11 Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Publications (1)

Publication Number Publication Date
SG11202010322XA true SG11202010322XA (en) 2020-11-27

Family

ID=62778848

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010322XA SG11202010322XA (en) 2018-06-14 2019-06-11 Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Country Status (13)

Country Link
US (1) US11813362B2 (en)
EP (1) EP3806828A1 (en)
JP (1) JP7266616B2 (en)
KR (1) KR20210003786A (en)
CN (1) CN112218623A (en)
AU (1) AU2019286326A1 (en)
BR (1) BR112020025112A2 (en)
CA (1) CA3103324A1 (en)
IL (1) IL279299A (en)
MX (1) MX2020013567A (en)
PH (1) PH12020551741A1 (en)
SG (1) SG11202010322XA (en)
WO (1) WO2019238647A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220113942A (en) * 2019-12-13 2022-08-17 스미토모 파마 가부시키가이샤 Small tablets with excellent manufacturability and dissolution
KR20230091684A (en) * 2021-12-16 2023-06-23 주식회사 종근당 Pharmaceutical combination comprising dapagliflozin and sitagliptin and preparing method thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287366A (en) 1963-12-24 1966-11-22 American Cyanamid Co Novel 1, 2-dihydro-s-triazines
CA2313776A1 (en) 1997-12-12 1999-06-24 Abbott Laboratories Triazine angiogenesis inhibitors
FR2804113B1 (en) 2000-01-26 2004-06-18 Lipha ANIMATED DIHYDRO-1,3,5-TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
FR2853650B1 (en) 2003-04-10 2006-07-07 Merck Sante Sas AMINE DEDOUBLING PROCESS USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INSULINO-RESISTANCE SYNDROME
AU2005206540B2 (en) 2004-01-20 2009-01-08 Merck & Co., Inc. Antidiabetic oxazolidinediones and thiazolidinediones
KR101006793B1 (en) 2005-08-11 2011-01-10 에스알유 바이오시스템즈, 인코포레이티드 Grating-based sensor combining label-free binding detection and fluorescence amplification and readout system for sensor
FR2896161B1 (en) 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si USE OF TRIAZINE DERIVATIVES FOR MANUFACTURING A MEDICAMENT HAVING A HEALING OR ANGIOGENIC EFFECT.
FR2896158B1 (en) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si COMBINATION OF TRIAZINE DERIVATIVES AND HMG-COA REDUCTASE INHIBITORS.
FR2896159B1 (en) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SENSITIZING AGENTS.
FR2896157B1 (en) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SECRETION STIMULATION AGENTS.
WO2008069222A1 (en) 2006-12-05 2008-06-12 Semiconductor Energy Laboratory Co., Ltd. Plasma display panel and field emission display
DE102007054416A1 (en) 2007-11-13 2009-05-14 Studiengesellschaft Kohle Mbh Process for the preparation of 3,6-dihydro-1,3,5-triazine derivatives for the treatment of diseases associated with insulin resistance syndrome
DE102008007314A1 (en) 2008-02-02 2009-08-06 Merck Patent Gmbh Process for the preparation of 3,6-dihydro-1,3,5-triazine derivatives
US20110124860A1 (en) 2008-05-23 2011-05-26 Aubourg Stephanie Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives
EA018508B1 (en) 2008-07-29 2013-08-30 Поксел Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization
KR101623819B1 (en) 2008-12-12 2016-05-24 뽁셀 에스아에스 Combination of insulin with triazine derivatives and its use for treating diabetes
MX2011005644A (en) 2008-12-12 2011-06-16 Poxel Tetrahydrotriazine compounds for treating diseases associated with ampk activity.
JP5600328B2 (en) 2009-02-13 2014-10-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical compositions comprising glucopyranosyldiphenylmethane derivatives, pharmaceutical dosage forms thereof, methods for their preparation and their use for improving glycemic control in patients
US8742102B2 (en) 2009-03-26 2014-06-03 Poxel Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
FR2948027A1 (en) 2009-07-17 2011-01-21 Merck Sante Sas DIHYDRO-1,3,5-TRIAZINE AMINO DERIVATIVES FOR THEIR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ISCHEMIA AND / OR REPERFUSION
TWI436768B (en) * 2010-06-09 2014-05-11 Poxel Treatment of type 2 diabetes
JP5707489B2 (en) 2010-06-09 2015-04-30 ポクセル・エスアーエスＰｏｘｅｌｓａｓ Treatment of type 1 diabetes
EA022300B1 (en) 2010-12-01 2015-12-30 Поксел Separation of 2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine enantiomers using tartaric acid
EP2468261A1 (en) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US20160151461A1 (en) 2013-03-14 2016-06-02 The Trustees Of The University Of Pennsylvania Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ITMI20130874A1 (en) * 2013-05-29 2014-11-30 Zambon Spa DEGLUTIBLE TABLETS OF N-ACETYLCISTEIN
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US10285973B2 (en) 2014-11-10 2019-05-14 Merck Sharp & Dohme Corp. SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
CN105990398B (en) 2015-02-16 2019-01-11 上海和辉光电有限公司 Organic light emitting diode display and its manufacturing method
KR20230028565A (en) 2016-03-16 2023-02-28 베링거 인겔하임 인터내셔날 게엠베하 Pharmaceutical composition comprising empagliflozin and uses thereof
KR20200102982A (en) 2017-10-02 2020-09-01 폭셀 Heart failure treatment method with preserved ejection rate
MX2020013210A (en) 2018-06-06 2021-02-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease.

Also Published As

Publication number Publication date
EP3806828A1 (en) 2021-04-21
WO2019238647A1 (en) 2019-12-19
KR20210003786A (en) 2021-01-12
JP7266616B2 (en) 2023-04-28
IL279299A (en) 2021-01-31
CA3103324A1 (en) 2019-12-19
US11813362B2 (en) 2023-11-14
MX2020013567A (en) 2021-05-27
PH12020551741A1 (en) 2021-06-07
CN112218623A (en) 2021-01-12
AU2019286326A1 (en) 2020-12-10
JP2021526506A (en) 2021-10-07
BR112020025112A2 (en) 2021-03-23
US20210212951A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
EP4010080C0 (en) Heterocyclic compounds for use in the treatment of cancer
PL3577135T3 (en) A pharmaceutical composition for use in the treatment or prevention of c5-related diseases
PL3720418T3 (en) Nicotine tablet
HK1254389A1 (en) Immediate-release tablets containing a drug and processes for forming the tablets
SG11202101611TA (en) Controlled-release urethane-elastomers for use in implantable products
IL279299A (en) Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
IL247969B (en) A therapeutic agent for use in the treatment of infections
GB201701400D0 (en) Compound for use in medicine
EP3806679C0 (en) Capsules for use in personal vaporizers
EP3338771A4 (en) Pharmaceutical composition of a combination of tramadol-etoricoxib hydrochloride for the treatment of pain
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
ZA201907286B (en) A pharmaceutical combination for the treatment of a cancer
HK1257593A1 (en) New drug for treating diabetes and use thereof
IL284074A (en) Decorin for use in the treatment of diabetes
CA185261S (en) Capsule for use in a personal vaporizer
IL283315A (en) Heterocyclic compounds and medical use thereof
IL268265B (en) 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment
IL273563A (en) A physiological compound for use in the treatment of osteoarthritic pain
GB201819776D0 (en) Medical process
PL3381423T3 (en) Cuff for orthotic treatment
GB201712192D0 (en) SmartDepo-(extended-release injections) a promising new drug treatment for addiction
GB201702652D0 (en) Delta-theraphotoxin-Ac1 for use in treating diabetes
GB201701388D0 (en) Compound for use in medicine
GB201702050D0 (en) Therapeutic moieties
GB201702046D0 (en) Therapeutic moieties